Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|79|3-4|204-210

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.3-4, 2011-03, pp. : 204-210

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 197-203

Karger

Access to resources Recommend Favorite

Weekly Docetaxel and Gemcitabine as First-Line Treatment for Metastatic Breast Cancer: Results of a Multicenter Phase II Study

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 438-445

Karger

Access to resources Recommend Favorite

A Multicenter Phase II Randomized Trial of Docetaxel/Gemcitabine versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Gruppo Oncologico Italia Meridionale Study

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 230-236

Karger

Access to resources Recommend Favorite

Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer

By  

Oncology, Vol. 80, Iss. 3-4, 2011-07 ,pp. : 262-268

Karger

Access to resources Recommend Favorite

Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 32, Iss. 1-2, 2009-01 ,pp. : 18-24

Karger

Access to resources Recommend Favorite